FY2029 Earnings Estimate for VERA Issued By Wedbush

Vera Therapeutics, Inc. (NASDAQ:VERA) – Research analysts at Wedbush issued their FY2029 earnings per share estimates for shares of Vera Therapeutics in a report issued on Thursday, February 27th. Wedbush analyst L. Chico forecasts that the company will earn $2.16 per share for the year. Wedbush currently has a “Neutral” rating and a $38.00 target price on the stock. The consensus estimate for Vera Therapeutics’ current full-year earnings is ($2.89) per share. Wedbush also issued estimates for Vera Therapeutics’ FY2029 earnings at $2.16 EPS.

Several other equities analysts have also issued reports on VERA. Wells Fargo & Company started coverage on Vera Therapeutics in a research report on Thursday, November 21st. They issued an “overweight” rating and a $70.00 price objective for the company. JPMorgan Chase & Co. boosted their price objective on Vera Therapeutics from $72.00 to $75.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Wolfe Research started coverage on Vera Therapeutics in a research report on Tuesday, February 4th. They issued an “outperform” rating and a $49.00 price objective for the company. Guggenheim boosted their price objective on Vera Therapeutics from $59.00 to $61.00 and gave the company a “buy” rating in a research report on Thursday. Finally, The Goldman Sachs Group started coverage on Vera Therapeutics in a research report on Tuesday, January 28th. They issued a “buy” rating and a $58.00 price objective for the company. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $65.11.

Vera Therapeutics Price Performance

Shares of VERA opened at $29.93 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. The stock has a 50 day simple moving average of $35.75 and a 200 day simple moving average of $40.31. Vera Therapeutics has a 52-week low of $25.99 and a 52-week high of $51.61. The firm has a market capitalization of $1.90 billion, a PE ratio of -11.47 and a beta of 1.11.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.11.

Insiders Place Their Bets

In other Vera Therapeutics news, CEO Marshall Fordyce sold 17,500 shares of the company’s stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $41.74, for a total transaction of $730,450.00. Following the completion of the transaction, the chief executive officer now owns 143,603 shares of the company’s stock, valued at $5,993,989.22. This represents a 10.86 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders sold a total of 52,500 shares of company stock valued at $2,305,625 in the last quarter. 21.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Vera Therapeutics

Large investors have recently made changes to their positions in the stock. Huntington National Bank acquired a new stake in shares of Vera Therapeutics in the 4th quarter valued at approximately $26,000. AlphaQuest LLC acquired a new stake in shares of Vera Therapeutics in the 4th quarter valued at approximately $34,000. GF Fund Management CO. LTD. acquired a new stake in shares of Vera Therapeutics in the 4th quarter valued at approximately $56,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Vera Therapeutics by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company’s stock valued at $86,000 after buying an additional 350 shares during the last quarter. Finally, KBC Group NV boosted its holdings in shares of Vera Therapeutics by 127.2% in the 4th quarter. KBC Group NV now owns 2,477 shares of the company’s stock valued at $105,000 after buying an additional 1,387 shares during the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.